BACKGROUND: It has been speculated that gender differences in @entity65 ( @entity65 ) mortality can be attributed to the effects of @entity172 on @entity32 and hemostatic marker profiles. Therefore, we evaluated endogenous hormone concentrations, menopause transition stages, and adoption of exogenous hormone use in relation to hemostatic and @entity32 marker concentrations in @entity1 . METHODS: Longitudinally, we studied 3302 @entity1 from the Study of @entity1 's Health Across the Nation, aged 42-52 yr at baseline and self-identified as African-American (28%), Caucasian (47%), Chinese (8%), Hispanic (8%), or Japanese (9%). Serum samples from baseline and years 2001, 2003, and 2005 were assayed for @entity53 and FSH. Hormone concentrations were related to @entity65 markers, including fibrinogen, factor VII-c, @entity2289 ( @entity2289 ), tissue plasminogen activator, and human serum @entity1851 (hsCRP). RESULTS: Lower @entity53 levels were associated with higher levels of @entity2289 and tissue plasminogen activator, but there were no significant relationships with fibrinogen, factor VII-c, or hsCRP. Higher FSH concentrations were associated with higher @entity2289 levels, but lower fibrinogen and hsCRP levels. Transitions from premenopause and early perimenopause to postmenopause were not associated with significant differences in levels of hemostatic factors. The hsCRP concentrations were approximately 25% higher, and the @entity2289 concentrations approximately 20% lower among @entity1 who initiated hormone therapy, compared with nonusers. SUMMARY: Endogenous @entity172 may reduce @entity65 risk via modulation of fibrinolytic factors, but not coagulation or inflammatory markers. Notably, conclusions derived from studies of exogenous hormones and @entity65 risk may not parallel or explain the effects of endogenous hormones or perimenopausal hormone changes on @entity65 risk.

Hemostatic factors and XXXX during the menopausal transition.

@entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogens'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity1 :: ('9606', 'Species') :: ['participants', 'women', 'Women'] @entity2289 :: ('5054', 'Gene') :: ['plasminogen activator inhibitor-1', 'PAI-1', 'PAI-1 and factor VII'] @entity53 :: ('MESH:D004958', 'Chemical') :: ['estradiol'] @entity65 :: ('MESH:D002318', 'Disease') :: ['CVD', 'cardiovascular disease'] @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein']
@entity172 :: (MESH:D004967,Chemical) :: ['estrogen']
